Apidra insulin is a form of insulin used to treat diabetes. It has an onset of action, or "peak time", of 2 1/2 to 5 hours.
Apidra is the only insulin product approved by the FDA that delivers fast-acting and basal insulin for people with diabetes living on a schedule of three or more daily injections, not including intensive management by continuous subcutaneous insulin infusion which requires specialized equipment.
When compared to human NPH insulin, Apidra worked more quickly and was equally as effective at lowering glucose levels over 24 hours in adult patients with type 2 diabetes mellitus who were using premixed insulins before switching to Apidra. In another study directly comparing Apidra with regular human insulin, both insulins worked equally well to lower glucose levels.